ABSTRACT: Depression is a chronic and debilitating illness that interferes severely with many human behaviors, and is the leading cause of disability in the world. There is data suggesting that deficits in serotonin neurotransmission can contribute to the development of depression. Indeed, >90% of prescribed antidepressant drugs act by increasing serotonergic transmission at the synapse. However, this increase is offset by a negative feedback operating at the level of the cell body of the serotonin neurons in the raphe nuclei. In the present work, we demonstrate: f irst, the intracortical infusion of ketamine induced an antidepressant-like effect in the forced swim test, comparable to that produced by systemic ketamine; second, systemic and intracortical ketamine increased serotonin and noradrenaline efflux in the prefrontal cortex, but not in the dorsal raphe nucleus; third, systemic and intracortical administration of ketamine increased the efflux of glutamate in the prefrontal cortex and dorsal raphe nucleus; fourth, systemic ketamine did not alter the functionality of 5-HT 1A receptors in the dorsal raphe nucleus. Taken together, these findings suggest that the antidepressant-like effects of ketamine are caused by the stimulation of the prefrontal projection to the dorsal raphe nucleus and locus coeruleus caused by an elevated glutamate in the medial prefrontal cortex, which would stimulate release of serotonin and noradrenaline in the same area. The impact of both monoamines in the antidepressant response to ketamine seems to have different time frames.
■ INTRODUCTION
Major depression, the most common of the psychiatric illnesses, is a severe and deteriorating condition that impacts several brain areas, impairing their normal functioning, for instance, nucleus accumbens (reward and motivation), amygdala (fear and anxiety), limbic system (sad mood), prefrontal cortex (cognitive impairment), and hypothalamus (vegetative symptoms). The serotonergic system originated in the dorsal raphe nucleus (DRN), through its vast innervation of all these brain regions, is in a critical position to influence these different behaviors and, therefore, has been implicated in the etiology of depression and its treatment. 1, 2 Likewise, the noradrenergic neurons concentrated in the nucleus locus coeruleus 3 are also relevant to the pharmacotherapy of depression. 4 Although much has been discussed in favor of or against a role of serotonin and/or noradrenaline in depression, it is indisputable that >90% of prescribed antidepressant drugs, the selective serotonin reuptake inhibitors (SSRIs) and the selective noradrenaline and serotonin uptake inhibitors (SNRIs), act by increasing these transmitters at the synapse. Interestingly, the sustained effect of recent antidepressant therapies, deep brain stimulation (DBS) and ketamine, seems to depend on an intact serotonin system in the brain. 5−7 However, despite the widespread use of SSRIs and SNRIs to treat depression, there is a lack of compelling evidence linking depression to low serotonergic and/or noradrenergic transmission.
Two of the principal limitations of current antidepressant drugs are their insufficient efficacy and therapeutic delay. Indeed, it is estimated that one-third of patients do not respond adequately to such medications. 8, 9 Even when there is a positive response, all available antidepressant drugs need to be administered for weeks or months to evoke a significant clinical improvement (i.e., 50% reduction of severity). More than two decades ago, our lab demonstrated for the first time that available antidepressant drugs increased the release of serotonin predominantly in the raphe region. 10 This excess of extracellular serotonin therein would stimulate raphe 5-HT 1A autoreceptors, 10, 11 thus leading to a reduced firing activity of serotonergic cells, with the consequent decrease of forebrain release of serotonin, an effect contrary to that required for the therapeutic response.
12,13 Accordingly, it was proposed that a therapy that combined an SSRI with a 5-HT 1A receptor antagonist, would reduce the latency of the antidepressant response.
14 This was later confirmed in part by several clinical studies 15 (see ref 16 for review). However, the add-on use of 5-HT 1A receptor antagonists failed to be advantageous to treat depression because the activation of forebrain 5-HT 1A receptors is necessary for an antidepressant response 17 and, in fact, prefrontal 5-HT 1A receptors have been reported to play a role in the antidepressant response to ketamine. 18 In line with these findings, recent preclinical work has shown that mice that overexpress 5-HT 1A receptors in the raphe region exhibit no behavioral response to antidepressant treatment. 19 In contrast, the selective reduction of the expression of presynaptic (raphe autoreceptor), but not postsynaptic (forebrain heteroreceptor) 5-HT 1A receptors by the use of small-interfering RNA (siRNA) targeted to serotonin neurons evoked strong antidepressant-like effects. 20 However, this strategy has not been tested so far in the clinical setting.
In the past decade, clinical investigations have shown that the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, produced a rapid (in only 2 h after a single intravenous bolus administration) and sustained (lasting up to 7 days) antidepressant action. 21−24 This finding has shaken up the field of pharmacotherapy for depression, thus evidencing that a faster antidepressant response is eventually possible. Although the mechanism of action of ketamine remains poorly understood, the involvement of several cellular processes has been uncovered. For instance, the rapid antidepressant-like action of ketamine requires the activation of a class of ionotropic glutamate receptors, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, 25−27 and the stimulation of mammalian target of rapamycin (mTOR), an intracellular pathway associated with synaptic plasticity. 28 Ketamine microinfusion into the infralimbic cortex reproduced the antidepressant-like actions of systemic ketamine 29, 30 and the muscimolinduced neuronal inactivation of the infralimbic prefrontal cortex fully blocked these behavioral effects of systemic ketamine. 29 Further, the direct stimulation of AMPA receptors in the medial prefrontal cortex (mPFC) by the full agonist (S)-AMPA also exerted an antidepressant response and increased the prefrontal efflux of 5-HT and glutamate. 31, 32 We have also shown that both systemic and bilateral (but not unilateral), intra-mPFC administration of ketamine increased serotonin efflux in the mPFC. 33, 34 However, infusion of ketamine into the DRN did not alter 5-HT efflux in the mPFC. 35 Overall this set of results seems to support the idea that prefrontal (infralimbic) 5-HT might contribute to the antidepressant-like effects of ketamine. Interestingly, we recently described that DBS of the infralimbic mPFC was able to release glutamate in the DRN, which in turn stimulated serotonin neurons in a way that 5-HT release occurred in the mPFC (terminal release) but not in the DRN (somatodendritic release), 31 thus precluding feedback inhibition of 5-HT cells by activation of 5-HT 1A autoreceptors.
This was consistent with the results obtained after the optogenetic stimulation of layer five pyramidal neurons of the mPFC 29,36−38 and would ultimately contribute to the rapid antidepressant-like response. Altogether, the important question that emerged was: what is the precise mechanism by which the stimulation of cortico-raphe projection (brought about by DBS, optogenetics or ketamine) evokes a rapid antidepressant response associated with increased prefrontal 5-HT? To solve this issue, we first examined whether the intra-mPFC infusion reproduced the antidepressant-like effects of systemic ketamine. Second, we asked whether ketamine could affect noradrenaline, 5-HT, and glutamate efflux in the mPFC and DRN.
■ RESULTS
Effects of Ketamine on the FST. As depicted in Figure 1 , one-way ANOVA showed that the administration of ketamine through both routes decreased immobility (F 3,12 = 7.576; p < 0.005) and increased climbing (F 3, 13 = 4.784; p < 0.02) in the FST without changing swimming behavior. This decreased immobility was brought about without significant changes in locomotor activity ( Figure S1 ). Also, as noted in a previous study, the intra-mPFC perfusion of ketamine did not produced hyperlocomotion. 34 Effects of Ketamine on 5-HT, Noradrenaline, and Glutamate Efflux. In the different experimental conditions of this work no significant differences among the basal extracellular levels of 5-HT, noradrenaline and glutamate in the mPFC and DRN were observed. Therefore, data was pooled and shown in Table S1 . Two-way repeated measures ANOVA showed that the systemic administration of ketamine dose-dependently increased 5-HT in the mPFC (Figure 2A ) as demonstrated by a significant effect of dose (F 2,15 = 6.633, p < 0.01), time (F 9,135 = 10.247, p < 0.0001), and treatment × time interaction (F 18,135 = 4.191, p < 0.0001). The increase of prefrontal 5-HT elicited by the dose of 25 mg/kg of ketamine was higher than that of 10 mg/ kg (p < 0.03). Results expressed in area under the curve (AUC) of the same treatments are represented in Figure 2B . In contrast, the same dosage produced no effect on the 5-HT efflux in the DRN ( Figure 2C ,D). Two-way repeated measures ANOVA also showed that the systemic administration of ketamine increased noradrenaline in the mPFC ( Figure 3A ) as demonstrated by significant effect of treatment (F 2,10 = 10.475, p < 0.005) and treatment × time interaction (F 18,99 = 2.158, p < 0.01). Results 
■ DISCUSSION
In this paper, we uncover a possible neurochemical mechanism by which ketamine may exert its rapid antidepressant effects. Here we demonstrated that both systemic and intracortical administration of ketamine elicits a rapid antidepressant-like response in the FST, in line with previous work. 29, 30 In contrast to what results from SSRIs treatment (increased swimming response in rats 39 ), increased climbing was observed 30 min after the administration of ketamine, which suggests that the rapid antidepressant-like response of ketamine might be rather due to a stimulation of noradrenaline transmission, which was also found herein. In line with the present results, previous work also reported that subanesthetic doses of ketamine increased the release of not only 5-HT, 33, 34 but also noradrenaline 40 as well as glutamate 41 in the mPFC. Interestingly, ketamine increased swimming behavior when FST was conducted 24 h after drug administration, 7 which concurs with previous work showing that short-term antidepressant response of ketamine is independent of serotonergic transmission. It is well-known that SSRIs elevate 5-HT transmission. However, this occurs first in the DRN before taking place in serotonergic nerve endings, 42 which would act as a brake of inducing forebrain 5-HT release and the subsequent antidepressant response. This effect has been proposed as being responsible of the delayed therapeutic action of these drugs. 14 Recently, it has been shown that the optogenetic stimulation of prefrontal projection to the DRN evokes antidepressant effects, 36−38 thus reproducing those elicited by intracortical administration of ketamine. 29 Interestingly, the systemic administration of ketamine increased substantially 5-HT efflux in the mPFC, but not in the DRN, coincident with previous work in mice 7 and similarly to what occurs after DBS of the infralimbic cortex. 31 This absence of alteration in extracellular 5-HT in the DRN was coincident with the finding that ketamine was unable to alter the stimulation of [
35 S]GTPγS induced by 8-OH-DPAT in the DRN. This strengthened the notion that ketamine did not modify the function of 5-HT 1A autoreceptors in the present experimental conditions, thus suggesting that the autoinhibitory control of raphe 5-HT 1A receptors was not altered. Further, systemic ketamine also stimulated the efflux of noradrenaline and glutamate in the mPFC, but only that of glutamate in the DRN. The lack of changes in 5-HT and noradrenaline efflux in the DRN suggests that ketamine do not stimulate evenly all noradrenergic and serotonergic neurons in the locus coeruleus and the DRN, respectively, but only subpopulations of them that project specifically to the mPFC. It has to be noted also that an action of ketamine in other regions that provide stimulatory input to the DRN 43 cannot be ruled out. Therefore, we hypothesize that ketamine activates mPFC, layer 5 pyramidal neurons that impact on noradrenergic and serotonergic neurons that project back to the mPFC. Two sets of investigations give further support to our view. First, recent evidence has shown that a subpopulation of mPFC glutamatergic neurons send axonal innervations to the DRN and locus coeruleus and acute pharmacogenetic activation of these neurons has antidepressant-like effects. 44 Second, ketamine increased AMPA-induced firing activity of pyramidal neurons, 45 and the activation of such neurons releases glutamate in the DRN that also stimulates AMPA receptors localized to serotonergic neurons, 35, 46, 47 which eventually evokes release of serotonin and stimulated 5-HT 1A receptors in the mPFC. 18 Our results further indicate that ketamine also exerts a similar influence upon noradrenergic neurons of the locus coeruleus. Changes in 5-HT and noradrenaline levels cannot be attributed to direct effects of 5-HT and/or noradrenaline transporters as earlier suggested 48 because recent publications 49, 50 and the K i database from the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP, https://pdsp.unc.edu/databases/kidb.php) have distinctly evidenced that ketamine displays no affinity for rat 5-HT and noradrenaline transporters.
The infusion of ketamine directly into the DRN did not change dialysate 5-HT and glutamate in the DRN and mPFC, in line with previous work, 35 which is concordant with the paucity of NMDA receptors found in this nucleus. 51 Thus, this is a scenario comparable to what we found following DBS of the infralimbic cortex, i.e., the activation of corticofugal neurons to and intra-mPFC 31 administration of AMPA agonists evoked a rapid antidepressant effect in the FST. In contrast, the infusion of AMPA into the DRN did not produce any local change in the extracellular concentration of 5-HT, 35, 53 but the intra-DRN injection of an AMPA receptor antagonist, abolished the increased efflux of 5-HT in the mPFC after systemic ketamine. 35 Indeed, both systemic and intracortical administration of ketamine increased the percentage of 5-HT cell bodies in the DRN showing c-Fos immunoreactivity, an effect blocked by microinjection of an AMPA receptor antagonist into the mPFC. 30 Although further research is needed to ascertain what mechanism is responsible for this particular kind of DRN stimulation, our results are coincident with those of Blier's group showing that enhanced 5-HT neurotransmission can be observed in projection areas after acute ketamine administration without changes in the firing activity of 5-HT neurons in the DRN. 45 Alternatively, it is also possible that the release of glutamate in the DRN could increase the firing activity of a subset of serotonergic neurons without a concomitant somatodendritic release of 5-HT in the nucleus. The influence upon noradrenergic neurons in the locus coeruleus would have a dissimilar mechanism inasmuch as ketamine did increase noradrenergic firing rate and bursting activity. 45 
■ CONCLUSION
In summary, although the monoamine deficiency hypothesis of depression has been questioned, the role of serotonin has regained importance because recent findings show that the sustained antidepressant response of glutamatergic drugs such as ketamine depend upon an intact serotonergic system. In the present work, we suggest that the rapid-antidepressant action of ketamine might rather be due to increased efflux of glutamate and noradrenaline in the mPFC, whereas 5-HT would be responsible for a more sustained effect of the drug. Forced Swim Test (FST). The FST was conducted as previously described by Cryan and co-workers. 54 Rats were handled daily for 1 week before FST. On day 1 (pretest), rats were placed in a clear plexyglas cylinder (46 cm height, 20 cm diameter) filled with 24 ± 1°C water to a height of 30 cm, for 15 min. After this pretest, animals were returned to their home cages and dried under a lamp for 30 min. The test was conducted and videotaped (ANY maze, Stoelting Europe, Dublin, Ireland) 24 h after the pretest session in the same cylinder for 5 min immediately following 1 h perfusion of ketamine bilaterally into the mPFC or 30 min after systemic administration of the drug (10 or 25 mg/kg). We chose 30 min after drug administration because at this time point the effect of ketamine on cortical transmitters is maximal. 33, 40, 41 The 5 min test session was divided into 5 s epochs. At the end of each epoch the predominant behavior was rated as immobility, climbing and swimming by an experimenter blind to the treatment.
Locomotor Activity. To check for unspecific changes in gross activity that would mask FST observations, locomotor activity was measured in an open field arena (100 cm × 100 cm × 40 cm) with plastic walls dimly lighted, and recorded during 10 min with a video camera connected to a computer (ANY maze).
Microdialysis Procedures. Concentric dialysis probes with a 4 mm Cuprophan (pore size 10 000 Da) membrane length were implanted bilaterally under 60 mg/kg i.p. pentobarbital anesthesia in the mPFC (AP +3.2 mm, L ±0.6 mm, DV −6.0 mm; from bregma), according to reference atlas. 55 In another set of microdialysis experiments, two probes were implanted in the mPFC and a third probe with a 2 mm Cuprophan membrane length was implanted in the dorsal raphe nucleus (DRN) (AP −7.8 mm, L −3.1 mm, DV −7.8 mm, with an angle of 30°to avoid the aqueduct). Microdialysis experiments were conducted 48 h after surgery in freely moving rats by continuously perfusing probes with aCSF (147 mM NaCl, 3 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 ) at a rate of 1 μL/min. Dialysate samples of 20 μL were collected in microvials containing 5 μL of 10 mM perchloric acid, every 20 min. At the completion of experiments, rats were given an overdose of sodium pentobarbital and the brains were then rapidly removed, frozen on dry ice, and stored at −80°C. Tissue sections were cut on a cryostat and probe placements were confirmed in histological sections stained with cresyl violet dye. Experimental data from misplaced probes were discarded. Noradrenaline, 5-HT and glutamate were determined using an Alexys Analyzer (Antec Scientific, Leiden, The Netherlands) following manufacturer's methods. 35 S]GTPγS binding assays. Labeling of brain sections was carried out as described previously 56 with some modifications. Slidemounted sections were preincubated for 30 min at room temperature in a buffer containing 50 mM Tris-HCl, 0.2 mM EGTA, 3 mM MgCl 2 , 100 mM NaCl, 1 mM DL-dithiothreitol and 2 mM GDP at pH = 7.7. Slides were subsequently incubated, for 2 h, in the same buffer containing adenosine deaminase (10 mU/mL) with [ Statistics. Data are expressed as mean ± SEM. FST data was analyzed by one-way analysis of variance (ANOVA) followed by post hoc Dunnett's tests for each behavior. Unless otherwise specified, microdialysis data were usually analyzed by two-way ANOVA for repeated measures, with treatment and time as main factors, followed by Tukey's post hoc tests. When only two variables were compared, two-tailed Student's t test was used. In all cases, the level of significance was set at p < 0.05. 
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